TY - JOUR
T1 - Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth
AU - Stoltz, David A.
AU - Meyerholz, David K.
AU - Pezzulo, Alejandro A.
AU - Ramachandran, Shyam
AU - Rogan, Mark P.
AU - Davis, Greg J.
AU - Hanfland, Robert A.
AU - Wohlford-Lenane, Chris
AU - Dohrn, Cassie L.
AU - Bartlett, Jennifer A.
AU - Nelson IV, George A.
AU - Eugene, Chang
AU - Taft, Peter J.
AU - Ludwig, Paula S.
AU - Estin, Mira
AU - Hornick, Emma E.
AU - Launspach, Janice L.
AU - Samuel, Melissa
AU - Rokhlina, Tatiana
AU - Karp, Philip H.
AU - Ostedgaard, Lynda S.
AU - Uc, Aliye
AU - Starner, Timothy D.
AU - Horswill, Alexander R.
AU - Brogden, Kim A.
AU - Prather, Randall S.
AU - Richter, Sandra S.
AU - Shilyansky, Joel
AU - McCray, Paul B.
AU - Zabner, Joseph
AU - Welsh, Michael J.
PY - 2010
Y1 - 2010
N2 - Lung disease causes most of the morbidity and mortality in cystic fibrosis (CF). Understanding the pathogenesis of this disease has been hindered, however, by the lack of an animal model with characteristic features of CF. To overcome this problem, we recently generated pigs with mutated CFTR genes. We now report that, within months of birth, CF pigs spontaneously developed hallmark features of CF lung disease, including airway inflammation, remodeling, mucus accumulation, and infection. Their lungs contained multiple bacterial species, suggesting that the lungs of CF pigs have a host defense defect against a wide spectrum of bacteria. In humans, the temporal and causal relations between inflammation and infection have remained uncertain. To investigate these processes, we studied newborn pigs. Their lungs showed no inflammation but were less often sterile than controls. Moreover, after introduction of bacteria into their lungs, pigs with CF failed to eradicate bacteria as effectively as wild-type pigs. These results suggest that impaired bacterial elimination is the pathogenic event that initiates a cascade of inflammation and pathology in CF lungs. Our finding that pigs with CF have a host defense defect against bacteria within hours of birth provides an opportunity to further investigate CF pathogenesis and to test therapeutic and preventive strategies that could be deployed before secondary consequences develop.
AB - Lung disease causes most of the morbidity and mortality in cystic fibrosis (CF). Understanding the pathogenesis of this disease has been hindered, however, by the lack of an animal model with characteristic features of CF. To overcome this problem, we recently generated pigs with mutated CFTR genes. We now report that, within months of birth, CF pigs spontaneously developed hallmark features of CF lung disease, including airway inflammation, remodeling, mucus accumulation, and infection. Their lungs contained multiple bacterial species, suggesting that the lungs of CF pigs have a host defense defect against a wide spectrum of bacteria. In humans, the temporal and causal relations between inflammation and infection have remained uncertain. To investigate these processes, we studied newborn pigs. Their lungs showed no inflammation but were less often sterile than controls. Moreover, after introduction of bacteria into their lungs, pigs with CF failed to eradicate bacteria as effectively as wild-type pigs. These results suggest that impaired bacterial elimination is the pathogenic event that initiates a cascade of inflammation and pathology in CF lungs. Our finding that pigs with CF have a host defense defect against bacteria within hours of birth provides an opportunity to further investigate CF pathogenesis and to test therapeutic and preventive strategies that could be deployed before secondary consequences develop.
UR - http://www.scopus.com/inward/record.url?scp=77952974496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952974496&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.3000928
DO - 10.1126/scitranslmed.3000928
M3 - Article
C2 - 20427821
AN - SCOPUS:77952974496
SN - 1946-6234
VL - 2
SP - 29ra31
JO - Science translational medicine
JF - Science translational medicine
IS - 29
ER -